Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Ney Carter Borges: Perioperative Cardiovascular Medication Management in Noncardiac Surgery
Apr 26, 2026, 11:38

Ney Carter Borges: Perioperative Cardiovascular Medication Management in Noncardiac Surgery

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“Perioperative Cardiovascular Medication Management (Noncardiac Surgery)

Key Clinical Recommendations (AHA/ACC 2024 Guideline – JAMA 2026)

Statins

  • Continue therapy perioperatively
  • Initiate in high-risk patients
  • Decreased mortality: 2.18% vs 3.15% (OR 0.62; 95% CI 0.58–0.67)

Aspirin

  • Continue if prior PCI
  • Do NOT initiate without PCI
  • Increased bleeding risk: 4.6% vs 3.8% (HR 1.23; p equals 0.04)

β-blockers

  • Continue if already prescribed
  • Avoid initiation perioperatively
  • Increased mortality: HR 1.33 (95% CI 1.03–1.74)

SGLT2 inhibitors

  • Suspend before surgery
  • 3 days: dapagliflozin / empagliflozin
  • 4 days: ertugliflozin
  • Reason: risk of euglycemic ketoacidosis

GLP-1 receptor agonists

  • Consider withholding (depending on case)
  • Risk: delayed gastric emptying – aspiration
  • Gastric residue: 11 vs 1 (p equals 0.004).”

Ney Carter Borges: Perioperative Cardiovascular Medication Management in Noncardiac Surgery

Other posts featuring Ney Carter Borges on Hemostasis Today.